PVLA

Palvella Therapeutics, Inc. Common Stock

24.45 USD
-0.94
3.70%
Updated Apr 28, 3:06 PM EDT
1 day
-3.70%
5 days
-5.01%
1 month
-12.99%
3 months
93.28%
6 months
43.82%
Year to date
103.75%
1 year
108.80%
5 years
-88.85%
10 years
-88.89%
 

About: Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Employees: 14

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

35.95% more ownership

Funds ownership: 0% [Q3] → 35.95% (+35.95%) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$38
55%
upside
Avg. target
$44
82%
upside
High target
$50
104%
upside

7 analyst ratings

positive
100%
neutral
0%
negative
0%
Chardan Capital
Geulah Livshits
10% 1-year accuracy
6 / 59 met price target
105%upside
$50
Buy
Initiated
9 Apr 2025
HC Wainwright & Co.
Andrew Fein
31% 1-year accuracy
110 / 352 met price target
55%upside
$38
Buy
Reiterated
1 Apr 2025
Stifel
Annabel Samimy
44% 1-year accuracy
4 / 9 met price target
84%upside
$45
Buy
Initiated
26 Mar 2025
Jones Trading
Catherine Novack
22% 1-year accuracy
2 / 9 met price target
84%upside
$45
Buy
Initiated
25 Mar 2025
Scotiabank
Louise Chen
25% 1-year accuracy
29 / 118 met price target
105%upside
$50
Sector Outperform
Initiated
7 Mar 2025

Financial journalist opinion

Based on 5 articles about PVLA published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
Neutral
GlobeNewsWire
6 days ago
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No.
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Neutral
GlobeNewsWire
2 weeks ago
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial Top-line results from SELVA remain on track for the first quarter of 2026 QTORIN™ 3.9% rapamycin anhydrous gel has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) was featured by Dr. Amy Paller in an oral presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina.
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
Neutral
GlobeNewsWire
3 weeks ago
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the upcoming 15th World Congress of Pediatric Dermatology, taking place April 8-11, 2025, in Buenos Aires, Argentina. The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations.
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
Neutral
GlobeNewsWire
4 weeks ago
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
1 month ago
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025.
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
Neutral
GlobeNewsWire
2 months ago
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com.
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Neutral
GlobeNewsWire
2 months ago
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Expansion reflects Palvella's commitment to serving all patients affected  by microcystic lymphatic malformations (microcystic LMs)
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Neutral
GlobeNewsWire
4 months ago
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Charts implemented using Lightweight Charts™